Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma - GBI Research Reports

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma - GBI Research Reports
Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma
Published Dec 31, 2011
86 pages — Published Dec 31, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma. The report provides in-depth analysis of drivers and barriers that impact the global Hospital Acquired Bacterial Infections (HABI) market. The report analyzes the markets for hospital acquired bacterial infections in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

The global hospital acquired bacterial infections market mainly comprises of four indications which are Urinary Tract Infections (UTI), pneumonia, Bloodstream Infections (BSI) and Surgical Site Infections (SSI). The total market of HABI is dependent on the major infections which are mainly caused by multi-drug resistant bacteria. Increasing human resistance to anti-bacterials leads to a need for advanced therapies to treat bacterial infections. Patent expiry of major antibacterials like Zyvox, Invanz, Tobi and Levaquin is set to erode the HABI market. This decline in the market will not be corrected by new product launches of pipeline molecules. Pharmaceutical companies show less interest in antibacterial R&D due to low Return on Investment (RoI). The lifespan of antibacterials is frequently limited due to the development of drug resistance. Big Pharma prefers acquiring small and niche pharmaceutical companies to widen their antibacterial pipeline portfolio.

The HABI market will show decline in the forecast period. The market is forecast to decline at a negative CAGR of 3.4% in the forecast period 20102017. Decline in the HABI market will be due to two main reasons. Firstly, there is resistance developed against antibacterials which makes existing antibacterials obsolete in some conditions. Secondly, there is an increase in hospital surveillance which leads to a decline in HABIs. Based on CDC data, 20% to 30% of hospital acquired infections can be prevented by infection control programs. There is formation of government bodies which are making it mandatory for hospitals to cut down on the spread of infections in the healthcare setup.

Scope

- Annualized market data for the HABI market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading therapeutic segments, including UTI, Pneumonia, SSI and BSI.
- Analysis of the HABI market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the HABI market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, J&J, Cubist and other niche companies like Trius Therapeutics and Tetraphase Pharmaceuticals.
- Key M&A activities, licensing agreements, that have taken place since 2004 in HABI market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic marke

  
Source:
Document ID
GBIHC174MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents36
  List of Tables52
  List of Figures72
Global Hospital Acquired Bacterial Infections Market - Introduction91
  GBI Research Report Guidance91
Global Hospital Acquired Bacterial Infections Market - Market Overview107
  Introduction101
  Revenue Forecasts for the Global Hospital Acquired Bacterial Infections Market111
    Sales Value111
      Branded Vs Generics121
    Annual Cost of Therapy131
    Treatment Usage Patterns141
      Diseased Population151
      Diagnosed Population151
      Prescription Population151
  Hospital Acquired Bacterial Infections Market Drivers151
    Increase in Antibacterial Resistance due to Their Frequent Usage151
    Threat from Emergence of Superbugs151
  Hospital Acquired Bacterial Infections Market Restraints161
    Increased Penetration of Generics Pose as a Threat for Primary Manufacturers161
    Increased Anti-bacterial Surveillance in Hospitals161
Global Hospital Acquired Bacterial Infections Market - Therapeutic Landscape1729
  Hospital Acquired Urinary Tract Infections (UTI) Market171
    Introduction171
    Sales Value172
    Annual Cost of Therapy191
    Treatment Flow Algorithm201
    Treatment Usage Patterns211
      Diseased Population221
      Diagnosed Population221
      Prescription Population221
    Market Share by Geography231
  Hospital Acquired Bacterial Pneumonia (HABP) Market241
    Introduction241
    Sales Value251
    Annual Cost of Therapy261
    Treatment Flow Algorithm271
    Treatment Usage Patterns281
      Diseased Population291
      Diagnosed Population291
      Prescription Population291
    Market Share by Geography301
  Hospital Acquired Bacterial Surgical Site Infections Market311
    Introduction311
    Sales Value312
    Annual Cost of Therapy331
    Treatment Flow Algorithm341
    Treatment Usage Patterns351
      Diseased Population361
      Diagnosed Population361
      Prescription Population361
    Market Share by Geography372
  Hospital Acquired Bacterial Blood Stream Infections (BSI) Market391
    Introduction391
    Sales Value391
    Annual Cost of Therapy401
    Treatment Flow Algorithm411
    Treatment Usage Patterns421
      Diseased Population431
      Diagnosed Population431
      Prescription Population431
    Market Share by Geography442
Global Hospital Acquired Bacterial Infections Market - Geographical Landscape4615
  Geographical Break-up462
  The US481
    Sales Value481
    Annual Cost of Therapy491
    Treatment Usage Patterns501
      Diseased Population511
      Diagnosed Population511
      Prescription Population511
  Top Five Countries in Europe521
    Sales Value521
    Country Segmentation531
    Annual Cost of Therapy541
    Treatment Usage Patterns551
      Diseased Population561
      Diagnosed Population561
      Prescription Population561
  Japan571
    Sales Value571
    Annual Cost of Therapy581
    Treatment Usage Patterns591
      Diseased Population601
      Diagnosed Population601
      Prescription Population601
Global Hospital Acquired Bacterial Infections - Pipeline Analysis617
  Pipeline Drugs by Phase of Development611
  Research and Development Pipeline611
    Phase III Pipeline Molecules611
    Phase II Pipeline Molecules621
    Phase I, Pre-Clinical and Discovery Phase Molecules631
  Profiles of Key Late Stage Drugs641
    Oritavancin641
      Overview641
      Mechanism of Action641
      Clinical Study Details641
    Torezolid651
      Overview651
      Mechanism of Action651
      Clinical Study Details651
    Ceftobiprole Medocaril661
      Overview661
      Mechanism of Action661
      Clinical Study Details661
    Omadacycline/ PTK 0796661
      Overview661
      Mechanism of Action661
      Clinical Study Details671
    Oritavancin671
      Overview671
      Mechanism of Action671
      Clinical Study Details671
Global Hospital Acquired Bacterial Infections Market - Competitive Landscape685
  Competitive Profiling681
    Johnson &Johnson (J&J)681
      Overview681
      Product Portfolio681
      SWOT Analysis691
    Pfizer691
      Overview691
      Product Portfolio691
      SWOT Analysis701
    Cubist Pharmaceuticals701
      Overview701
      Product Portfolio701
      SWOT Analysis711
    Bayer711
      Overview711
      Product Portfolio711
      SWOT Analysis721
    Trius Therapeutics721
      Overview721
    Tetraphase Pharmaceuticals Inc.721
      Overview721
Global Hospital Acquired Bacterial Infections Market - Strategic Consolidations736
  Overview731
  M&A Deals by Geography731
  M&A Deals by Value741
  M&A Deals by Deal Type751
    Merck Completes Acquisition Of Inspire Pharmaceuticals751
    SciClone Pharmaceuticals Acquires NovaMed Pharmaceuticals761
    AstraZeneca Completed the Acquisition of Novexel SA in March 2010761
  R&D Licensing Agreements761
    Major Licensing Agreements771
      Trius Therapeutics Enters into Licensing Agreement with Bayer HealthCare for Torezolid Phosphate771
      Furiex Pharmaceuticals Enters Into Licensing Agreement with Janssen Pharmaceutica for JNJ-Q2771
      AMRI Enters Into Licensing Agreement with Genentech781
      Optimer Pharmaceuticals Enters into Licensing Agreement with Astellas Pharma Europe for Fidaxomicin781
      Anacor Pharmaceuticals Enters Into Licensing Agreement with GlaxoSmithKline in July 2010781
Global Hospital Acquired Bacterial Infections Market - Appendix798
  Market Definitions791
  Abbreviations791
  Research Methodology806
    Coverage801
    Secondary Research801
    Primary Research811
    Therapeutic Landscape811
      Epidemiology-Based Forecasting822
    Market Size by Geography841
    Geographical Landscape851
    Pipeline Analysis851
    Competitive Landscape851
    Expert Panel Validation851
  Contact Us851
  Disclaimer851
  Sources861

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma" Dec 31, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Hospital-Acquired-Bacterial-Infections-Market-to-2017-Niche-Players-are-Most-Active-in-R-D-Positioning-Them-as-Potential-Acquisition-Targets-for-Big-Pharma-2115-323>
  
APA:
GBI Research Reports. (2011). Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma Dec 31, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Hospital-Acquired-Bacterial-Infections-Market-to-2017-Niche-Players-are-Most-Active-in-R-D-Positioning-Them-as-Potential-Acquisition-Targets-for-Big-Pharma-2115-323>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.